Avacta Group (LON:AVCT) Sets New 12-Month High – Here’s What Happened

Avacta Group Plc (LON:AVCT)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as GBX 83.20 and last traded at GBX 80, with a volume of 2869779 shares trading hands. The stock had previously closed at GBX 81.

Analyst Upgrades and Downgrades

Separately, Peel Hunt reissued a “buy” rating and issued a GBX 99 price target on shares of Avacta Group in a research note on Monday, October 13th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, Avacta Group presently has a consensus rating of “Buy” and an average target price of GBX 99.

Avacta Group Trading Down 1.2%

The company has a quick ratio of 4.96, a current ratio of 1.29 and a debt-to-equity ratio of 52.53. The stock has a market capitalization of £326.61 million, a price-to-earnings ratio of -4.56 and a beta of 1.12. The company’s 50-day moving average is GBX 64.85 and its 200-day moving average is GBX 48.23.

Avacta Group (LON:AVCT) last released its quarterly earnings data on Tuesday, September 30th. The biotechnology company reported GBX (4.46) EPS for the quarter. Avacta Group had a negative net margin of 114.45% and a negative return on equity of 74.00%. Research analysts anticipate that Avacta Group Plc will post -9.9011833 earnings per share for the current fiscal year.

Avacta Group Company Profile

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).